These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 38677652)

  • 41. [Thrombotic microangiopathy following kidney transplantation revealing factors H and I deficiencies].
    Fraison JB; Pernin V; Alméras C; Vetromile F; Frémeaux-Bacchi V; Mourad G
    Rev Med Interne; 2011 Jun; 32(6):e81-3. PubMed ID: 20667630
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Primary antiphospholipid syndrome presented as thrombotic microangiopathy in renal transplantation.
    Bada-Bosch T; Redondo B; Sevillano AM; Alonso M; Trujillo H; Auñón P; Polanco N; Rodríguez L; Gonzalez E; Andrés A
    Nefrologia (Engl Ed); 2020; 40(1):108-110. PubMed ID: 31431303
    [No Abstract]   [Full Text] [Related]  

  • 43. Thrombotic micro-angiopathy with sirolimus-based immunosuppression: potentiation of calcineurin-inhibitor-induced endothelial damage?
    Robson M; Côte I; Abbs I; Koffman G; Goldsmith D
    Am J Transplant; 2003 Mar; 3(3):324-7. PubMed ID: 12614289
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Everolimus, cyclosporine, and thrombotic microangiopathy: clinical role and preventive tools in renal transplantation.
    Nava F; Cappelli G; Mori G; Granito M; Magnoni G; Botta C; Solazzo A; Fontana F; Baisi A; Bonucchi D
    Transplant Proc; 2014 Sep; 46(7):2263-8. PubMed ID: 25242766
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Survey of thrombotic microangiopathy within 1 week after kidney transplantation between 2010 and 2015 in Japan.
    Satoh S; Saito K; Harada H; Okumi M; Saito M;
    Clin Exp Nephrol; 2019 Apr; 23(4):571-572. PubMed ID: 30539337
    [No Abstract]   [Full Text] [Related]  

  • 46. The inferior impact of antibody-mediated rejection on the clinical outcome of kidney allografts that develop de novo thrombotic microangiopathy.
    Wu K; Budde K; Schmidt D; Neumayer HH; Lehner L; Bamoulid J; Rudolph B
    Clin Transplant; 2016 Feb; 30(2):105-17. PubMed ID: 26448478
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Thrombotic microangiopathy following haematopoietic stem cell transplant.
    Seaby EG; Gilbert RD
    Pediatr Nephrol; 2018 Sep; 33(9):1489-1500. PubMed ID: 28993886
    [TBL] [Abstract][Full Text] [Related]  

  • 48. De Novo and Recurrent Thrombotic Microangiopathy After Renal Transplantation: Current Concepts in Management.
    Abbas F; Abbas SF
    Exp Clin Transplant; 2022 Jun; 20(6):549-557. PubMed ID: 34546154
    [TBL] [Abstract][Full Text] [Related]  

  • 49. De novo thrombotic microangiopathy after non-renal solid organ transplantation.
    Verbiest A; Pirenne J; Dierickx D
    Blood Rev; 2014 Nov; 28(6):269-79. PubMed ID: 25266355
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Tacrolimus-induced severe cholestasis complicating renal transplantation.
    Yadav DK; Gera DN; Gumber MR; Kute VB; Patel MP; Vanikar AV; Trivedi HL
    Ren Fail; 2013; 35(5):735-7. PubMed ID: 23560366
    [TBL] [Abstract][Full Text] [Related]  

  • 51. A rare case of colic thrombotic microangiopathy in renal transplantation.
    Rizza V; Coletti G; Mazzotta C; Clemente K; Di Cocco P; Del Reno F; Margiotta G; Famulari A; Pisani F
    Transplant Proc; 2010 May; 42(4):1362-4. PubMed ID: 20534302
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The safety of calcineurin inhibitors for kidney-transplant patients.
    Malvezzi P; Rostaing L
    Expert Opin Drug Saf; 2015 Oct; 14(10):1531-46. PubMed ID: 26329325
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Calcineurin Inhibitor Nephrotoxicity Through the Lens of Longitudinal Histology: Comparison of Cyclosporine and Tacrolimus Eras.
    Nankivell BJ; PʼNg CH; OʼConnell PJ; Chapman JR
    Transplantation; 2016 Aug; 100(8):1723-31. PubMed ID: 27306529
    [TBL] [Abstract][Full Text] [Related]  

  • 54. High-dose mizoribine combined with calcineurin inhibitor (cyclosporine or tacrolimus), basiliximab and corticosteroids for renal transplantation: A Japanese multicenter study.
    Nishioka T; Yoshimura N; Ushigome H; Watarai Y; Nishimura K; Akioka K; Nakamura N; Kawakita M; Yuzawa K; Nakatani T
    Int J Urol; 2018 Feb; 25(2):141-145. PubMed ID: 29068092
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Combination of calcineurin and mTOR inhibitors in kidney transplantation: a propensity score analysis based on current clinical practice.
    Cucchiari D; Ríos J; Molina-Andujar A; Montagud-Marrahi E; Revuelta I; Ventura-Aguiar P; Piñeiro GJ; De Sousa-Amorim E; Esforzado N; Cofán F; Torregrosa JV; Ugalde-Altamirano J; Ricart MJ; Rovira J; Torres F; Solè M; Campistol JM; Diekmann F; Oppenheimer F
    J Nephrol; 2020 Jun; 33(3):601-610. PubMed ID: 31853792
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Diagnosis of de novo localized thrombotic microangiopathy by surveillance biopsy.
    Hastings MC; Wyatt RJ; Ault BH; Jones DP; Lau KK; Gaber AO; Gaber LW
    Pediatr Nephrol; 2007 May; 22(5):742-6. PubMed ID: 17216252
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Treatment of Tacrolimus-associated thrombotic microangiopathy in renal transplant recipient with fresh frozen plasma: A case report.
    Kais H; Nourredine C; Raoudha B; Emira C; Tarek S; Fehmi S; Ezzedine B; Jalel H; Jamel M
    Saudi J Kidney Dis Transpl; 2006 Mar; 17(1):58-61. PubMed ID: 17297539
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Safety of Everolimus With Reduced Calcineurin Inhibitor Exposure in De Novo Kidney Transplants: An Analysis From the Randomized TRANSFORM Study.
    Tedesco-Silva H; Pascual J; Viklicky O; Basic-Jukic N; Cassuto E; Kim DY; Cruzado JM; Sommerer C; Adel Bakr M; Garcia VD; Uyen HD; Russ G; Soo Kim M; Kuypers D; Buchler M; Citterio F; Hernandez Gutierrez MP; Bernhardt P; Chadban S;
    Transplantation; 2019 Sep; 103(9):1953-1963. PubMed ID: 30801548
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Evaluating the efficacy, safety and evolution of renal function with early initiation of everolimus-facilitated tacrolimus reduction in de novo liver transplant recipients: Study protocol for a randomized controlled trial.
    Nashan B; Schemmer P; Braun F; Dworak M; Wimmer P; Schlitt H
    Trials; 2015 Mar; 16():118. PubMed ID: 25873064
    [TBL] [Abstract][Full Text] [Related]  

  • 60. De novo thrombotic microangiopathy in renal allograft biopsies-role of antibody-mediated rejection.
    Satoskar AA; Pelletier R; Adams P; Nadasdy GM; Brodsky S; Pesavento T; Henry M; Nadasdy T
    Am J Transplant; 2010 Aug; 10(8):1804-11. PubMed ID: 20659088
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.